|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our studies demonstrate that as a tumour suppressor, miR-3188 directly targets mTOR to stimulate its own expression and participates in FOXO1-mediated repression of cell growth, tumorigenesis and NPC chemotherapy resistance.
|
27095304 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In hormone-negative breast cancers lacking human epidermal growth factor receptor 2 (HER2) amplification, we find that RUNX1 down-regulation is strongly associated with up-regulation of FOXO1, which may be required to support growth of RUNX1-negative tumors.
|
21873240 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with NC + Vector group, mimics + Vector group has higher OD495 value (<i>P</i> < 0.05), higher migration and invasion cells (<i>P</i> < 0.01), larger transplanted tumor volume (<i>P</i> < 0.01), lower FOXO1 positive cell numbers (<i>P</i> < 0.01), higher p-AKT and p-GSK-3β expression (<i>P</i> < 0.01), lower p-β-catenin expression (<i>P</i> < 0.01), more β-catenin expression in the nucleus (<i>P</i> < 0.01).
|
30828264 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the nuclei of cells incubated with S109 accumulated tumor suppressor proteins (Foxo1, p27 and IκB-α).
|
26055813 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Forkhead box O-class 1 (FOXO1), a putative tumor suppressor, is dysregulated in many cancers.
|
22213032 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that targeting FOXO1, which is at the convergence point of several growth factor receptor tyrosine kinase pathways, can effectively induce glioma cell death and inhibit tumor growth.
|
19549905 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-96 can be considered as one of tumor-inducer and form competing endogenous RNA network with FOXO1 and DUSP1, which affects downstream EGFR signaling.
|
31579447 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, FOXO1 inhibited cell proliferation and tumor formation both <i>in vitro</i> and <i>in vivo</i>, and promoted pancreatic cancer cell invasion.
|
31217876 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, AFU showed a sufficient inhibitory effect on the phosphorylation of FOXO1, a tumor suppressor, in monotherapy or in combination with PD, which may be attributable to the activation of FOXO1, the subsequent inhibition of tumor growth, and the induction of cell death.
|
29928335 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Standard cytogenetic analyses and RT-PCR testing for the classic gene rearrangements seen in RMS [t(2;13)-PAX3/FKHR] and EWS ([t(11;22) & t(21;22)-EWS/FLI-1 & EWS/ERG), were used for characterization of the MEM, with gene expression microarray analyses on all tumor types.
|
17431644 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, we propose that the miR27-FOXO1 tandem inhibits apoptosis and represents an alternative pathway for tumor cell survival in PIK3CA-nonmutated EEC.
|
24746199 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that FOXO1a is a potent and specific tumor suppressor in ARMS, suggesting that agents that restore or augment FOXO1a activity may be effective as ARMS therapeutics.
|
16157701 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study shows a marked loss of AMP-activated protein kinase (AMPK) phosphorylation and nuclear human Forkhead box O1 (FOXO1) protein in estrogen-dependent endometrial cancer (EC) tumors compared to normal control endometrium.
|
27636742 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Forkhead box O1 (FOXO1) is a critical tumor suppressor for cell proliferation control.
|
24398626 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors.
|
16381018 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, two of these genes have been found to produce neoplasia (qin and FKHR).
|
7576194 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, decrease of FOXO1 or miR-194 was statistically significant between stages T1 and T2, whereas increase of miR-135b discriminated tumor stage T3a versus T1/T2.
|
24631529 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of caveolin-1 and FoxO1 protein at tumor microvessels was enhanced and caveolae-mediated CTB endocytosis was increased by NS1619 infusion for 15min.
|
27653874 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we showed that the forkhead box O (FOXO1) protein, a key downstream effector of the tumor suppressor PTEN, inhibits the transcriptional activity of Runx2 in prostate cancer cells.
|
21505104 |
2011 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The pathway from PAX3-FKHR translocation to the development of rhabdomyosarcoma tumors has been further elucidated.
|
19295433 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our study revealed miR-411 promoted cell proliferation of lung cancer by targeting tumor suppressor gene FOXO1 and miR-411 might be a potential target for lung cancer therapy.
|
26572153 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction analysis of messenger RNA for EWS-FLI1 and PAX-FKHR fusion transcripts and the human achaete-scute homolog-1 gene was performed on 24 of the 52 sinonasal tumors and the 19 tumors of other sites for comparison.
|
19150107 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, miR-1288 overexpression in ESCC cells showed repression of cytoplasmic tumour suppressor FOXO1 protein expression.
|
27658568 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After the diagnosis, cfDNA was serially collected to detect the PAX3-FOXO1 fusion sequence as a tumor marker. cfDNA could be an appropriate source for detecting the fusion gene; assays using cfDNA have proved to be useful for the early detection of tumor progression/recurrence.
|
30739374 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas ARMS tumors typically contain translocations generating PAX3-FOXO1 or PAX7-FOXO1 fusions that block terminal myogenic differentiation, no functionally comparable genetic event has been found in ERMS tumors.
|
24793135 |
2014 |